Orchid Pharma Limited Bombay S.E.

Equities

ORCHPHARMA

INE191A01027

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:48 2024-04-30 am EDT 5-day change 1st Jan Change
1,077 INR -0.84% Intraday chart for Orchid Pharma Limited +2.37% +50.95%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Orchid Pharma Limited Announces Resignation of Mudit Tandon as Independent Director CI
Orchid Pharma Receives United States Food and Drug Administration Approval for Its Novel Invention CI
Transcript : Orchid Pharma Limited, Q3 2024 Earnings Call, Feb 09, 2024
Orchid Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
European Medicines Agency Grants Approval for Orchid Pharma's 'Exblifep' CI
Orchid Pharma Limited Appoints Kapil Dayya as Company Secretary & Compliance Officer CI
Orchid Pharma Limited Announces Resignation of Marina Peter as Company Secretary and Compliance Officer CI
Orchid Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Orchid Pharma Limited Approves the Appointment of Mr. Arjun Dhanuka as Additional Director (In Capacity of Non-Executive & Non-Independent) CI
Orchid Pharma Ties Up with GARDP to Manufacture Antibiotic for Certain Gram-Negative Infections MT
Orchid Pharma Limited Enters into Manufacturing Sub License Agreement with Global Antibiotic Research & Development Partnership CI
Orchid Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Orchid Pharma Raises INR4 Billion Via Qualifed Institutional Placement MT
Orchid Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
CARE Upgrades Rating on Orchid Pharma's Long-term Bank Financing to BBB; Outlook Stable MT
Orchid Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Orchid Pharma Limited Announces Demise of Arun Kumar Dhanuka, Non-Executive & Non-Independent Director CI
Orchid Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Orchid Pharma : UK drugs regulator to halt approvals for Indian clinical trials firm RE
Chart Orchid Pharma Limited
More charts
Orchid Pharma Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of integrated active pharmaceutical ingredients (API). It operates through the pharmaceutical segment. It has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular segment (CVS), nutraceuticals and other oral and sterile products. Its pharmaceutical solutions include active pharmaceutical ingredients (APIs) and finished dosage forms. It offers APIs, including Cephalosporins-Orals, Cephalosporins-Injectables, Veterinary Products and Non-Antibodies. Its formulations include Cefixime Capsules, Acarbose Tablets, Acarbose Tablets, Clozapime Tablets, Clopidogrel Tablets, Desloratadine Tablets and Cefoperazone and Sulbactam for Injection, among others. Its subsidiaries include Orchid Europe Limited, Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc., and Diakron Pharmaceuticals, Inc., among others.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1,088 INR
Average target price
1,130 INR
Spread / Average Target
+3.86%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. ORCHPHARMA Stock
  4. ORCHPHARMA Stock
  5. News Orchid Pharma Limited
  6. Orchid Pharma Signs Deal to Convert Rupee Loan to Foreign Currency Debt